Thanks, Neil, and Dave. Starting with revenue, we generated revenue of $169.8 million, up 14.2% year-over-year and above the high end of our Q3 guidance range of $163 million to $165 million, or up 10% to 11%. From a channel perspective, retail revenue increased 20.7% year-over-year, while e-commerce revenue increased 3% versus Q3 of 2022. For the third quarter, e-commerce represented 33% of our overall business compared to 37% in 2022 and in line with our pre-pandemic channel mix. As Neil mentioned, the positive inflection in e-commerce revenue was driven by marketing spend, returning to growth, and the continued scaling of our contact business, the majority of which is online. As Neil mentioned, while we were encouraged by the growth we saw in Q3, we don't expect the e-commerce recovery to be linear and may see some periods of higher or lower growth in the near-term, including in Q4. Looking ahead, we believe that the overall trend line is positive and our e-commerce business is on a path towards sustainable growth. We opened 11 new stores in Q3 and 40 over the past 12 months, finishing Q3 with 227 stores. Retail productivity in Q3 was 101% versus the same period last year. As a reminder, we define retail productivity as sales per average number of stores open in the period. So even as we continue to add an average of 40 stores per year, our more mature cohorts continue to perform as those newer stores ramp. Seven of the new stores in Q3 were expansions within existing markets and four were entries into new markets. All 11 new stores include eye exam capabilities, which brought the number of locations offering eye exams in the quarter to 183, or 81% of our total fleet of 227 locations. From a customer perspective, we finished the quarter with 2.3 million active customers, an increase of 1.8% versus the same period a year ago, and our average revenue per customer increased 10% year-over-year to $284. As Neil mentioned, we're pleased with our increase in average revenue per customer, which was driven by a few factors, including an increase in progressives as a percentage of our business mix and continued ramping of both contact lens and eye exam sales. Progressives represented 22.5% of total prescription glasses sold in Q3 2023, up from 21.4% when compared to the third quarter of 2022. This is still well below the market average of approximately 40%, leaving a substantial runway for product category growth. Progressives are also our highest gross margin and highest price point product starting at $295. We also continue to make progress on our move into holistic vision care as we evolve from a glasses-only brand into one that offers glasses, contacts, and eye exams to customers. From Q3 2022 to Q3 2023, contact lenses have increased from 6.9% to 9.3% of our business mix. Over the same period, eye care has increased from 3.2% to 4.4% of our business mix. Contacts and eye exams both represent large opportunities for future growth, each accounting for $15 billion plus portions of the $76 billion U.S. optical industry. We remain well underpenetrated for sales of these products as a percent of revenue versus other national optical retailers. Moving on to gross margin. As a reminder, our gross margin accounts for a range of costs including frames, lenses, optical labs, customer shipping, optometrist salaries, store rents, and the depreciation of store build-outs. Our gross margin also includes stock-based compensation expense for our optometrists and optical lab employees. For comparability, I will be speaking to adjusted gross margin, which excludes stock-based compensation. Third quarter adjusted gross margin was 54.8% compared to 54.7% in Q2 of this year and 56.9% in Q3 of last year. The year-over-year decrease was driven by strong growth of eye exams and contact lenses as we evolve into a holistic vision care company and expand into these large segments of the optical industry. Eye exams and contacts have lower gross margin profiles than eyeglasses but over the medium and long-term are accretive to gross margin dollars and allow us to serve all of our customers eye care needs. Furthermore, expanding our contacts offering is a core part of scaling our holistic vision care offering and a key driver of growing average revenue per customer. In addition, contact lenses have a higher purchase frequency and subscription like purchase cycle. We also experienced continued year-over-year gross margin deleverage in two areas that represent the more fixed portion of our cost of goods, retail occupancy and optometrist salaries, which are directly linked to our expansion into eye care. Our growth in-store count has naturally led to an increase in store rent and depreciation from store build-outs. In Q3 specifically, we opened 11 new stores as of the end of Q3, 2023, we operated with 140 stores where we engaged directly with an optometrist and therefore recognized both revenue from exams and optometrist salaries. This represents an increase of 31% or 33 additional locations from 107 employed and PC exam stores at the end of the third quarter last year. We believe this ongoing investment in eye exam capabilities will benefit the business long-term as a result of greater control over the customer experience, new eye exam revenue, and higher in-store conversion rates. There are a few accretive tailwinds to margin that act to partially offset these effects. First, we continue to scale our highest priced and highest gross margin progressives business. In the third quarter, progressives accounted for 22.5% of our prescription eyeglass units, which is up 110 basis points versus a year ago. Secondly, we continue to scale the portion of prescription glasses orders that we in-source at our two owned optical labs in New York and Nevada. We expect our continued scaling at these facilities to result in continued gross margin benefits along with higher Net Promoter Scores, lower refund rates, and faster turnaround times. Shifting gears to SG&A. As a reminder, SG&A for our business includes three main components: salary expense covering our headquarters, customer experience and retail employees; marketing spend, including our home try-on program; and general corporate overhead expenses. Adjusted SG&A excludes non-cash costs like stock-based compensation expense, depreciation and charitable equity donations. Adjusted SG&A in the quarter was $93.4 million, or 55% of revenue compared to Q3 2022 adjusted SG&A of $82.3 million, or 55.3% of revenue. The 30 basis point decrease in adjusted SG&A as a percentage of revenue was primarily due to adjustments to our cost structure we made in August of last year, including lower salary and general corporate expenses partially offset by a planned increase in marketing spend. In Q3 of this year, we began anniversarying these pullbacks in SG&A spend driven by reductions in marketing and salary spend in particular. For the first nine months of this year, adjusted SG&A spend as a percent of revenue was 52.6% versus 59.1% for the same period last year, a decrease of 650 basis points. Marketing spend for the quarter came in at $19.7 million, or 11.6% of revenue. This is up from $14.9 million and 10% of revenue in the same period last year, driven in part by our new brand campaign aimed at driving longer-term awareness of Warby Parker. Turning now to adjusted EBITDA. In the third quarter, we generated adjusted EBITDA of $11 million, representing an adjusted EBITDA margin of 6.5%, which compares to adjusted EBITDA of $11.9 million or 8% of revenue in the year ago period. For the nine months ended September of this year, we generated adjusted EBITDA of $42.9 million and adjusted EBITDA margin of 8.5% compared to adjusted EBITDA of $18.6 million and adjusted EBITDA margin of 4.1% for the same period last year. On a year-to-date basis, we've increased adjusted EBITDA margin by 440 basis points compared to last year. Turning now to our balance sheet. We finished the quarter with a strong balance sheet position reflecting $216 million in cash, which we will continue to deploy deliberately to support our growth and operations. We also have an undrawn credit facility of $100 million, other than $4 million for letters of credit that we can upsize to $175 million. Now to our outlook. Based on our strong year-to-date performance and updated view of the rest of 2023, we're raising the full-year guidance we outlined on our Q2 call in August. For 2023, we now expect net revenue of $666 million to $669 million, representing approximately 11.5% growth at the mid-point of our range. Adjusted EBITDA margin of approximately 7.9% in line with prior guidance, which equates to adjusted EBITDA of $52.7 million at the mid-point of our top-line guidance range. We still expect gross margin in the mid-50s as a percent of revenue and to open 40 new stores this year. We're still forecasting stock-based compensation as a percentage of net revenue in 2023 to be roughly 10%, compared with 16% in 2022. Stock-based compensation for both years is above our long-term forecast as the result of the multi-year equity grants to our Co-CEOs in 2021. We still anticipate stock-based compensation to normalize to a range of 2% to 4% of net revenue late in 2024. With respect to the fourth quarter, we're guiding to the following. Net revenue of $158 million to $161 million, or revenue growth of approximately 8% to 10%. Through the first week of November, we've observed trailing 28-day retail productivity versus 2022 of 100%. From a bottom line perspective, we're guiding to an adjusted EBITDA margin of approximately 6% at the mid-point of our revenue guidance. With that, Neil, Dave and I are pleased to take your questions. Operator, please open the line for Q&A.